<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02717221</url>
  </required_header>
  <id_info>
    <org_study_id>14400</org_study_id>
    <nct_id>NCT02717221</nct_id>
  </id_info>
  <brief_title>In Vivo EGFR Molecular Classification</brief_title>
  <official_title>An EGFR-TKIs Benefit Non-small Cell Lung Carcinoma Patients Identification Strategy Using Molecular Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Harbin Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators developed 18F-MPG as a targeted molecular imaging agent for noninvasive and
      repeatable detecting EGFR-activating mutational status.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of investigators were to evaluate the use of 18F-MPG as a novel PET/CT radiotracer
      to monitor EGFR-activating mutational status and identify EGFR-TKIs benefit NSCLC patients.
      the investigators want to evaluated the use of 18F-MPG in lung cancer imaging in adult NSCLC
      patients with different EGFR mutational status of primary and metastatic cancers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>tumor SUVmax value of 18F-MPG PET/CT Imaging</measure>
    <time_frame>at time of imaging</time_frame>
    <description>To quantify the accumulation, a volume of interest using a 3-D sphere, was placed over the primary lung tumor, lymph nodes and distant metastases avoiding necrosis, blood vessels and normal lung tissue as much as possible on a workstation (Advantage Workstation 4.6; GE Healthcare). The maximum standard uptake value (SUVmax) normalized to body weight (kBq/mL) was calculated within the region of interest.</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Molecular Imaging</condition>
  <arm_group>
    <arm_group_label>18F-MPG:EGFR+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group had EGFR-activating mutant tumors and did not receive any treatment before this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-MPG:post-TKI EGFR+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with EGFR-activating mutant tumors were receiving EGFR-TKIs during this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-MPG:post-chemo EGFR+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with EGFR-activating mutant tumors were receiving chemotherapy during this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-MPG:EGFR wild type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group had EGFR wild-type tumors and did not receive any treatment before this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-MPG:post-chemo EGFR wild type</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group had EGFR wild-type tumors and were receiving chemotherapy during this study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>18F-MPG:unknown EGFR mutational status</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients without the EGFR mutational status measurement results and did not receive any treatments were classified in this group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>18F-MPG</intervention_name>
    <description>N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)</description>
    <arm_group_label>18F-MPG:EGFR+</arm_group_label>
    <arm_group_label>18F-MPG:post-TKI EGFR+</arm_group_label>
    <arm_group_label>18F-MPG:post-chemo EGFR+</arm_group_label>
    <arm_group_label>18F-MPG:EGFR wild type</arm_group_label>
    <arm_group_label>18F-MPG:post-chemo EGFR wild type</arm_group_label>
    <arm_group_label>18F-MPG:unknown EGFR mutational status</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced NSCLC

          -  18 years or older

          -  A life expectancy of at least 12 weeks

          -  Presence of a malignant lesion within the chest of at least 0.5 cm diameter as
             measured by computed tomography (CT)

          -  Written informed consent

        Exclusion Criteria:

          -  Claustrophobia

          -  Pregnancy

          -  Metal implants in the thorax
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baozhong Shen, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Fourth Hospital of Harbin Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xilin Sun, M.D.</last_name>
    <phone>86-15904601908</phone>
    <email>sunxilin@aliyun.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>TOF-PET/CT/MR center of the Fourth Hospital of Harbin Medical University</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150028</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xilin Sun, M.D.</last_name>
      <phone>86-15904601908</phone>
      <email>sunxilin@aliyun.com</email>
    </contact>
    <contact_backup>
      <last_name>Kai Wang, M.D.</last_name>
      <phone>86-13796601005</phone>
      <email>wangkai366@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Slobbe P, Windhorst AD, Stigter-van Walsum M, Smit EF, Niessen HG, Solca F, Stehle G, van Dongen GA, Poot AJ. A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice. EJNMMI Res. 2015 Mar 20;5:14. doi: 10.1186/s13550-015-0088-0. eCollection 2015.</citation>
    <PMID>25853020</PMID>
  </reference>
  <reference>
    <citation>Abourbeh G, Itamar B, Salnikov O, Beltsov S, Mishani E. Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET. EJNMMI Res. 2015 Feb 12;5:4. doi: 10.1186/s13550-014-0080-0. eCollection 2015.</citation>
    <PMID>25853010</PMID>
  </reference>
  <reference>
    <citation>Petrulli JR, Sullivan JM, Zheng MQ, Bennett DC, Charest J, Huang Y, Morris ED, Contessa JN. Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain. Neoplasia. 2013 Dec;15(12):1347-53.</citation>
    <PMID>24403856</PMID>
  </reference>
  <reference>
    <citation>Yeh SH, Lin CF, Kong FL, Wang HE, Hsieh YJ, Gelovani JG, Liu RS. Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA. Biomed Res Int. 2013;2013:549359. doi: 10.1155/2013/549359. Epub 2013 Jul 17.</citation>
    <PMID>23956990</PMID>
  </reference>
  <reference>
    <citation>Yeh HH, Ogawa K, Balatoni J, Mukhapadhyay U, Pal A, Gonzalez-Lepera C, Shavrin A, Soghomonyan S, Flores L 2nd, Young D, Volgin AY, Najjar AM, Krasnykh V, Tong W, Alauddin MM, Gelovani JG. Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT. Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1603-8. doi: 10.1073/pnas.1010744108. Epub 2011 Jan 10.</citation>
    <PMID>21220318</PMID>
  </reference>
  <reference>
    <citation>Pal A, Balatoni JA, Mukhopadhyay U, Ogawa K, Gonzalez-Lepera C, Shavrin A, Volgin A, Tong W, Alauddin MM, Gelovani JG. Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas. Mol Imaging Biol. 2011 Oct;13(5):853-61. doi: 10.1007/s11307-010-0408-8.</citation>
    <PMID>20859697</PMID>
  </reference>
  <reference>
    <citation>Zannetti A, Iommelli F, Speranza A, Salvatore M, Del Vecchio S. 3'-deoxy-3'-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer. J Nucl Med. 2012 Mar;53(3):443-50. doi: 10.2967/jnumed.111.096503. Epub 2012 Feb 13.</citation>
    <PMID>22331221</PMID>
  </reference>
  <reference>
    <citation>Gerbaudo VH, Kim CK. PET Imaging-Based Phenotyping as a Predictive Biomarker of Response to Tyrosine Kinase Inhibitor Therapy in Non-small Cell Lung Cancer: Are We There Yet? Nucl Med Mol Imaging. 2017 Mar;51(1):3-10. doi: 10.1007/s13139-016-0453-6. Epub 2016 Oct 11.</citation>
    <PMID>28250852</PMID>
  </reference>
  <reference>
    <citation>Nakamura Y, Ohler ZW, Householder D, Nagaya T, Sato K, Okuyama S, Ogata F, Daar D, Hoa T, Choyke PL, Kobayashi H. Near Infrared Photoimmunotherapy in a Transgenic Mouse Model of Spontaneous Epidermal Growth Factor Receptor (EGFR)-expressing Lung Cancer. Mol Cancer Ther. 2017 Feb;16(2):408-414. doi: 10.1158/1535-7163.MCT-16-0663. Epub 2016 Nov 15.</citation>
    <PMID>28151706</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2016</study_first_submitted>
  <study_first_submitted_qc>March 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2016</study_first_posted>
  <last_update_submitted>March 30, 2017</last_update_submitted>
  <last_update_submitted_qc>March 30, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Harbin Medical University</investigator_affiliation>
    <investigator_full_name>Xilin Sun</investigator_full_name>
    <investigator_title>Chief</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

